Cytogen Report issue

Contributed to NME For profit Phase 1 Phase 2
Founded: Princeton NJ United States (1980)
Status: Acquired by EUSA (2008) → now Jazz Pharmaceuticals (2012)

Organization Overview

First Clinical Trial
2003
NCT00328614
First Marketed Drug
1992
satumomab pendetide (Oncoscint)
First NDA Approval
1992
satumomab pendetide (Oncoscint)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CYTOGEN | Cytogen Corporation | CytoGen, Inc.